Inflammatory Biomarkers Predict Chronic Pulmonary Disease Outcome
By LabMedica International staff writers Posted on 03 Apr 2012 |
Changes in inflammatory biomarkers establish clinical variables and improve the prediction of mortality in patients with chronic obstructive pulmonary disease (COPD).
COPD is characterized by low-grade systemic inflammation and the addition of inflammatory biomarker blood tests would establish predictive factors that will improve accuracy of a prognostic model for mortality.
An international multicenter team of scientists led by those at Brigham and Women’s Hospital (Boston, MA, USA) prospectively collected data on 1,843 COPD patients from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Of these 1,843 patients, 168 (9.1%) died during the three-year follow-up.
The biomarkers measured from serum samples were: Chemokine (C-C motif) ligand 18 (CCL-18 or pulmonary and activation-regulated chemokine, PARC), surfactant protein D (SP-D), interleukin 8 (IL-8), Clara cell secretory protein 16 (CC-16), and tumor necrosis factor alpha (TNFα). Fibrinogen and C-reactive protein (CRP using a high sensitivity method) were measured in plasma samples. All protein biomarkers were measured by validated immunoassays. Total white blood cells (WBC) and neutrophils were counted by an automated method.
The results of the study show that a panel of selected biomarkers, WBC counts, IL-6, fibrinogen, CCL-18, CRP, IL-8, and SP-D were not only elevated in nonsurvivors compared with survivors, but were also associated with mortality over three years after adjusting for clinical variables known to predict death in COPD. Bartolome M. Celli, MD, the lead author of the study, said, "Adding white blood cell counts and measurement of changes in systemic levels of IL-6, CRP, IL-8, fibrinogen, CCL-18, and SP-D significantly improves the ability of clinical variables to predict mortality in patients with COPD. This is the first study to show that the addition of biomarker levels to clinical predictors in COPD patients adds relevant prognostic information." The study was published on March 23, 2012, in the American Journal of Respiratory and Critical Care Medicine.
Related Links:
Brigham and Women’s Hospital
COPD is characterized by low-grade systemic inflammation and the addition of inflammatory biomarker blood tests would establish predictive factors that will improve accuracy of a prognostic model for mortality.
An international multicenter team of scientists led by those at Brigham and Women’s Hospital (Boston, MA, USA) prospectively collected data on 1,843 COPD patients from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Of these 1,843 patients, 168 (9.1%) died during the three-year follow-up.
The biomarkers measured from serum samples were: Chemokine (C-C motif) ligand 18 (CCL-18 or pulmonary and activation-regulated chemokine, PARC), surfactant protein D (SP-D), interleukin 8 (IL-8), Clara cell secretory protein 16 (CC-16), and tumor necrosis factor alpha (TNFα). Fibrinogen and C-reactive protein (CRP using a high sensitivity method) were measured in plasma samples. All protein biomarkers were measured by validated immunoassays. Total white blood cells (WBC) and neutrophils were counted by an automated method.
The results of the study show that a panel of selected biomarkers, WBC counts, IL-6, fibrinogen, CCL-18, CRP, IL-8, and SP-D were not only elevated in nonsurvivors compared with survivors, but were also associated with mortality over three years after adjusting for clinical variables known to predict death in COPD. Bartolome M. Celli, MD, the lead author of the study, said, "Adding white blood cell counts and measurement of changes in systemic levels of IL-6, CRP, IL-8, fibrinogen, CCL-18, and SP-D significantly improves the ability of clinical variables to predict mortality in patients with COPD. This is the first study to show that the addition of biomarker levels to clinical predictors in COPD patients adds relevant prognostic information." The study was published on March 23, 2012, in the American Journal of Respiratory and Critical Care Medicine.
Related Links:
Brigham and Women’s Hospital
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines